Wayne Fagan, MD
MOHS-Micrographic Surgery · Corpus Christi, TXNPI 1942206180
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 125 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AbbVie accounts for 67.1% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2022 at $766 and has fallen 54.8% since, to $346 in 2025.
Across 125 payments — averaging $19.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novartis$277
- Sanofi$114
- E.r. Squibb & Sons, L.L.C.$96
- Johnson & Johnson$88
- Strata Skin Sciences, Inc.$35
- plus $188 from 10 others
What the payments were for
- Food & beverage$2,421100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 80 | $1,624 |
| Novartis | 16 | $277 |
| Sanofi | 4 | $114 |
| E.r. Squibb & Sons, L.L.C. | 6 | $96 |
| Johnson & Johnson | 5 | $88 |
| Strata Skin Sciences, Inc. | 2 | $35 |
| Mylan Pharmaceuticals Inc. | 2 | $27 |
| Genentech USA, Inc. | 2 | $25 |
| Mayne Pharma Commercial LLC | 1 | $21 |
| LEO Pharma Inc. | 1 | $21 |
| UCB, Inc. | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Springworks Therapeutics, Inc. | 1 | $16 |
| Sebela Pharmaceuticals Inc. | 1 | $15 |
| Dermavant Sciences, Inc. | 1 | $14 |
| Aclaris Therapeutics, Inc. | 1 | $12 |
How this compares
$2,421 in reported general payments places this provider in the 60th percentile of 109 mohs-micrographic surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Acitretin | 19 | $3,235 |
| Imiquimod | 31 | $3,095 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 1,374 | $2,826 |
| Fluorouracil | 19 | $1,326 |
| Ciprofloxacin Hcl | 185 | $607 |
| Doxycycline Hyclate | 17 | $131 |
| Tramadol Hcl | 17 | $26 |
Paid to pharmacies, not to this prescriber.
Other mohs-micrographic surgery in Corpus Christi
- Ryan RogersCorpus Christi$1K
- Aaron FarbergRockwall$1.5M
- Suneel ChilukuriBellaire$288K
- Ryan O QuinnSan Antonio$167K
- Paul FriedmanHouston$131K
- Brent SpencerFrisco$45K
- Julie CroleyThe Woodlands$30K
- Kayla McNieceBellaire$13K
- Hubert ChodkiewiczCedar Park$13K
- Meredith OrsethCedar Hill$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.